These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36727879)

  • 1. Complete Metabolic Response by 18 F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
    Uchida Y; Yoh T; Fukui A; Takai A; Hatano E
    Clin Nucl Med; 2023 May; 48(5):417-419. PubMed ID: 36727879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
    Kawamura Y; Kobayashi M; Shindoh J; Matsumura M; Okubo S; Muraishi N; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
    Oncology; 2022; 100(6):320-330. PubMed ID: 35231914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
    Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
    Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of [
    Li S; Peck-Radosavljevic M; Ubl P; Wadsak W; Mitterhauser M; Rainer E; Pinter M; Wang H; Nanoff C; Kaczirek K; Haug A; Hacker M
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1732-1741. PubMed ID: 28555333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography.
    Ferda J; Ferdová E; Baxa J; Kreuzberg B; Daum O; Třeška V; Skalický T
    Anticancer Res; 2015 Apr; 35(4):2241-6. PubMed ID: 25862885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
    Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
    World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
    Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.
    Castilla-Lièvre MA; Franco D; Gervais P; Kuhnast B; Agostini H; Marthey L; Désarnaud S; Helal BO
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):852-859. PubMed ID: 26577938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
    Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
    BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
    Park S; Kim TS; Kang SH; Kim HB; Park JW; Kim SK
    Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-induced modulation of glucose transporter expression impacts
    Xia H; Chen J; Gao H; Kong SN; Deivasigamani A; Shi M; Xie T; Hui KM
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):787-797. PubMed ID: 31832727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
    Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
    J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using
    Hyun SH; Eo JS; Song BI; Lee JW; Na SJ; Hong IK; Oh JK; Chung YA; Kim TS; Yun M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):720-726. PubMed ID: 29167923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
    Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.